Physician profile
Nicolette Christopher
NPI 1114442126
$7,881.18
in general payments reported to CMS, 2019-2025
31 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $923 · 2022: $1,316 · 2023: $1,058 · 2024: $2,107 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,460 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,460.49 |
| Education | $181.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,209.03 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,061.94 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $837.42 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $591.91 | 2021-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $353.63 | 2021-2025 | Rebyota |
| Lilly USA, LLC | $262.64 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $262.22 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $247.39 | 2022-2025 | Dupixent |
| Pfizer INC. | $202.01 | 2022-2025 | |
| Braintree Laboratories, INC. | $183.64 | 2022-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $173.07 | 2022-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $153.93 | 2021-2025 | Ocaliva |
| Genzyme Corporation | $145.43 | 2022-2025 | |
| Exact Sciences Corporation | $144.31 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $135.43 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $117.06 | 2024-2025 | Vowst, Zenpep |
| Janssen Scientific Affairs, LLC | $109.89 | 2021 | |
| Celltrion USA INC. | $88.92 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $84.83 | 2025 | Voquezna |
| Organon LLC | $80.24 | 2023-2025 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $78.56 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $69.75 | 2022-2025 | |
| Qol Medical, LLC | $65.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.35 | 2021-2024 | Dificid |
| Sandoz INC. | $39.16 | 2025 | Hyrimoz |
| Madrigal Pharmaceuticals | $32.34 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2024 | Cyltezo |
| Novo Nordisk INC | $19.89 | 2023 | Wegovy |
| Redhill Biopharma INC. | $18.56 | 2021 | |
| Celgene Corporation | $17.41 | 2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolette Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.